RecruitingNAINTERVENTIONAL

Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

This study aims to understand how a common treatment for lung cancer and head and neck cancer affects the body's immune system. Specifically, it focuses on 'T cells', which are special cells that fight off cancer. Patients receiving a combination of radiation therapy and chemotherapy at the same time will have blood and other samples collected. By studying these samples, researchers can see how the cancer-fighting T cells change during and after treatment. This information could help doctors develop more effective ways to use the immune system to fight cancer in the future.

At a glance

Status

Recruiting

Phase

Sponsor

Centre Hospitalier Universitaire de Besancon

Enrolment target

220

Start

29 May 2017

Estimated completion

29 Nov 2026

Lung Cancer Head and Neck Cancer

What is this study about?

When you have cancer, your body has natural defenses, including special cells called T cells that try to fight off the cancer. Treatments like radiation and chemotherapy are very important, but scientists are still learning exactly how they affect these natural cancer-fighting cells in the body.

This study is for people who have been diagnosed with lung cancer or head and neck cancer and are going to have a specific type of treatment. This treatment is called 'concomitant radiochemotherapy,' which simply means you'll be getting both radiation therapy and chemotherapy at the same time. The main goal is to carefully examine blood and other samples from these patients to see what happens to their T cells during and after this combined treatment.

By understanding how the immune system responds to this common treatment, researchers hope to find new ways to boost the body's own ability to fight cancer. This could lead to better and more personalised treatments for patients with lung and head and neck cancers in the future.

Key takeaways

This study investigates how common cancer treatments affect the body's immune system.
It focuses on patients with lung cancer or head and neck cancer receiving combined radiation and chemotherapy.
Participation mainly involves providing blood and other samples.
No new medications are given; you receive your standard care.
Your involvement could help improve future cancer treatments.

Who may be eligible?

This study is looking for adults aged 18 and over who have been diagnosed with either lung cancer (non-small cell or small cell type) or head and neck cancer. You must be planned to receive a specific kind of treatment where you have both radiation therapy and chemotherapy at the same time, as your first main treatment.

There are also some reasons why you might not be able to join. For example, if you're having only radiation therapy, or only chemotherapy, or if you've already had radiation and chemotherapy for cancer before. If you're currently taking certain medications that affect your immune system, or if you have specific conditions like HIV or hepatitis B or C, you wouldn't be able to take part.

Also, if you have a serious medical or mental health condition that would make it difficult to participate safely, or if you're under legal guardianship, you wouldn't be eligible. Everyone who takes part must also be able to understand and sign a consent form.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have lung cancer or head and neck cancer?
Are you scheduled to have radiation and chemotherapy at the same time for your first treatment?
Are you generally in good health apart from your cancer?
Are you able to understand and sign a consent form?

Answer every question to see your result.

What does participation involve?

This is primarily an observational study, meaning you would continue to receive your standard medical care as planned by your doctors. The main thing involved in taking part would be providing blood and potentially other biological samples (like biopsies if already planned for your treatment) at specific times during and after your radiation and chemotherapy. There are no new or experimental medications involved. The total duration of your participation would depend on your treatment schedule and follow-up, which the study team would explain fully.

Potential risks and benefits

Participating in this study might not directly benefit you, as the main goal is to gather information for future research. However, your contribution could help doctors understand cancer better and improve treatments for others. The risks involved are generally low, mainly related to providing blood samples, which may include slight discomfort or bruising. You can choose to stop participating in the study at any time without affecting your medical care.

Locations (4)

CHU de Besançon
Verified postcode
Besançon, France· Recruiting
Centre Georges François LECLERC
Verified postcode
Dijon, France· Recruiting
Hôpital Nord Franche-Comté
Verified postcode
Montbéliard, France· Recruiting
Institut Jean Godinot
Verified postcode
Reims, France· Recruiting

Common questions

What kind of cancer patients are you looking for?

We are looking for adults with lung cancer (both non-small cell and small cell) or head and neck cancer.

What kind of treatment do participants need to be having?

You need to be planned to receive radiation therapy and chemotherapy at the same time, as your first main treatment for your cancer.

Will I receive a new medicine?

No, this study does not involve new medications. You will receive your standard treatment as recommended by your doctors.

What do I have to do if I join?

You will mostly be providing blood samples at different times during your treatment. Other samples may be collected if already part of your medical plan.

Can I leave the study at any time?

Yes, you can choose to stop participating in the study at any point without it affecting the medical care you receive.

How to find out more

Olivier ADOTEVI, Pr

olivier.adotevi@univ-fcomte.fr +33370632212 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.